DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% (dextrose)
**Anticoagulant Citrate Dextrose (ACD) Solution A** is an anticoagulant intended for use only with medical devices that prepare Platelet Rich Plasma (PRP) products. It is used exclusively for extracorporeal (outside the body) blood processing. The solution maintains blood in a fluid state during processing, allowing clinicians to effectively isolate and concentrate platelets for clinical use. IMPROVED_HOW_IT_WORKS: **Anticoagulant Citrate Dextrose (ACD) Solution A** prevents blood from clotting by binding free calcium ions, which are essential co-factors in the coagulation cascade. The sodium citrate in the solution acts as the primary anticoagulant by sequestering these ions. Additionally, the solution contains citric acid for pH regulation and dextrose to maintain isotonicity. This solution is intended for extracorporeal use and has no direct pharmacological effect on the patient's body. *** **Note:** If you actually intended to summarize **Dextrose 5% and Potassium Chloride 0.15%**, the summary should instead focus on fluid and electrolyte replenishment (providing calories via glucose and replacing potassium/chloride losses). Please clarify which drug you need the summary for.
How DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% Works
This solution works by binding free calcium ions in the blood, which are essential co-factors for several steps in the natural clotting cascade. By removing available calcium, the sodium citrate in the solution prevents the blood from coagulating during processing. The solution also contains citric acid to regulate pH and dextrose to maintain isotonicity, though it has no direct pharmacological effect on the body.
Details
- Status
- Prescription
- First Approved
- 2020-09-10
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% Approval History
What DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% Treats
1 indicationsDEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% is approved for 1 conditions since its original approval in 2020. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Extracorporeal preparation of Platelet Rich Plasma (PRP)
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Clinical Trial Registry
13 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT07494084 | R01HL177106 R01HL177106 | Ph 4 | not yet recruiting | Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance |
| NCT04895358 | 3475-B49 MK-3475-B49, KEYNOTE-B49 | Ph 3 | active not recruiting | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) |
| NCT05264727 | 22-000306 R01DK116231 | Ph 4 | active not recruiting | Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion |
| NCT04020601 | Pro00092897 | Ph 2, Ph 3 | terminated | The Impact of a Preoperative Nerve Block on the Consumption of Sevoflurane in Total Shoulder Arthroplasty |
| NCT02471690 | MDCO-ORI-15-01 | Ph 1 | completed | Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers |
| NCT03095651 results posted | 5160-002 MK-5160-002 | Ph 1 | completed | Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002) |
| NCT02269735 | 2640-001 | Ph 1 | completed | A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001) |
| NCT00578669 results posted | PHI0710-002 1R01DA023190 | Ph 3 | completed | Sequential Use of Fluoxetine for Smokers With Elevated Depressive Symptoms |
| NCT01547364 | SweetCaudal | Ph 2 | completed | Caudal Epidural Injection of Dextrose For Low Back Pain |
| NCT02984098 40%D-N-PP | POSDRU/159.5/S/133377 | Ph 4 | completed | 40% Orally Administered Dextrose Gel is More Effective Than 25% Dextrose |
| NCT02185729 TPN1 results posted | IRB00007543 | Ph 2, Ph 3 | completed | Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers |
| NCT00878878 results posted | GE-191-004 | Ph 4 | completed | Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR). |
| NCT01326611 | rö05053781128 | Ph 4 | completed | Efficacy of Clarithromycin Treatment in Prevention of Chronic Lung Disease in Premature Infants |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% FDA Label Details
Indications & Usage
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% is indicated for the treatment of Extracorporeal preparation of Platelet Rich Plasma (PRP).
Track DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.